GlassScriptPhysician profile
Viola V Anderson
NPI 1700870540
$840.55
in general payments reported to CMS, 2019-2025
15 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.91 · 2022: $234 · 2023: $238 · 2024: $223 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $291.37 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $83.68 | 2022 | |
| Exact Sciences Corporation | $77.15 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $67.73 | 2022-2023 | Arexvy |
| Novo Nordisk INC | $54.65 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.50 | 2023-2024 | |
| Inspire Medical Systems, INC. | $36.38 | 2025 | Inspire |
| Zimmer Biomet Holdings, INC. | $32.23 | 2025 | Persona |
| Lilly USA, LLC | $31.69 | 2022-2023 | Jardiance, Zepbound |
| Astellas Pharma US INC | $28.19 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $22.29 | 2023 | Nexletol |
| Merck Sharp & Dohme LLC | $21.17 | 2024 | Capvaxive |
| Abbvie INC. | $16.08 | 2022 | |
| Amgen INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viola Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.